Clinical Trial: ALTO-207 in Adults With Treatment-resistant Depression (TRD)

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553637) titled 'ALTO-207 in Adults With Treatment-resistant Depression (TRD)' on March 31.

Brief Summary: The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Treatment-resistant Depression (TRD)

Intervention: DRUG: ALTO-207

ALTO-207 BID

DRUG: Placebo

Matching Placebo

Recruitment Status: RECRUITING

Sponsor: Alto Neuroscience

Disclaimer: Curated by HT Syndication....